Erasca (ERAS) Gets a Buy from J.P. Morgan
In a report released on March 28, Anupam Rama from J.P. Morgan maintained a Buy rating on Erasca (ERAS – Research Report). The company’s shares ...
Fintel on MSN4d
Raymond James Initiates Coverage of Erasca (ERAS) with Outperform Recommendation
Fintel reports that on March 26, 2025, Raymond James initiated coverage of Erasca (NasdaqGS:ERAS) with a Outperform ...
Yahoo Finance4d
Erasca, Inc. (ERAS)
Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential first-in-class examples of direct SMP ...
Business Insider4d
Erasca initiated with an Outperform at Raymond James
Raymond James analyst Laura Prendergast initiated coverage of Erasca (ERAS) with an Outperform rating and $5 price target. Raymond James believes that the near-term commercial opportunity for ...
Yahoo Finance5d
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting
SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies ...